OR WAIT null SECS
- Advertise
- About Us
- Editorial Board
- Contact Us
- Job Board
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2021 MJH Life Sciences™ and Infection Control Today. All rights reserved.
WHO Issues Interim Guidance on the Use of Delamanid in the Treatment of MDR-TB
A new TB drug with a novel mechanism of action – delamanid - is now available for treatment of adults with multidrug-resistant tuberculosis (MDR-TB), a form of tuberculosis resistant to at least isoniazid and rifampicin, the main first-line drugs. Delamanid was granted conditional approval by the European Medicine Agency in April 2014. Information about this new drug however remains limited, since it has only been through Phase IIb trial and studies for safety and efficacy.
The World Health Organization (WHO) is therefore issuing interim policy guidance that lists five conditions that must be in place if delamanid is used to treat adults with MDR-TB:
1. Proper patient inclusion: Special caution is required when delamanid is used in people aged 65 and over, in adults living with HIV, patients with diabetes, hepatic or severe renal impairment, or those who use alcohol or substances. Use in pregnant and breastfeeding women and children is not advised.
2. Adherence to WHO recommendations when designing MDR-TB treatment regimens: When delamanid is included in treatment, all principles on which WHO-recommended MDR-TB treatment regimens are based must be followed, particularly the inclusion of four effective second-line drugs as well as pyrazinamide. Delamanid should not be introduced alone into a regimen in which the companion drugs are failing to show effectiveness.
3. Effective treatment and monitoring: Treatment must be closely monitored for effectiveness and safety, using sound treatment and management protocols that have been approved by the relevant national authorities.
4. Pharmacovigilance and management of adverse events: active pharmacovigilance measures must be in place to ensure early detection and proper management of adverse drug reactions and potential interactions with other drugs.
5. Informed consent: Patients must be fully aware of the potential benefits and harms of the new drug, and give informed consent before embarking on treatment
WHO strongly recommends the acceleration of Phase III trials to generate a more comprehensive evidence base to inform future policy on delamanid. WHO will review, revise, or update the interim guidance as additional information on efficacy and safety become available. WHO has also developed an operational document to facilitate delamanid implementation and is working with partners to help ensure safe and effective introduction.
WHO estimates that about half a million new cases of MDR-TB occur worldwide, each year. Current treatment regimens for MDR-TB present many challenges: treatment lasts 20 months or more, requiring daily administration of drugs that are more toxic, less effective, and far more expensive than those used to treat drug-susceptible TB. Globally, less than half of all patients who start MDR-TB therapy are treated successfully. Wider availability of new drugs and shorter regimens will be essential if treatment outcomes of MDR-TB patients are to improve.
In 2013, another new drug, bedaquiline, was made available for use in the treatment of MDR-TB. Bedaquiline was the first new TB drug with a novel mechanism of action to be made available for more than 40 years and was granted accelerated approval by the Food and Drug Administration. It is still in Phase III trials and WHO urges caution in its use and strict adherence to conditions listed in the WHO interim policy guidance issued in June 2013.
Source: WHO